S&P 500   3,385.39 (+0.15%)
DOW   27,942.37 (-0.12%)
QQQ   274.52 (+0.98%)
AAPL   461.35 (+2.06%)
MSFT   211.24 (+0.98%)
FB   263.09 (+1.23%)
GOOGL   1,527.18 (+1.32%)
AMZN   3,205.43 (+1.37%)
NVDA   464.00 (+1.40%)
CGC   17.36 (+0.64%)
BABA   254.51 (-0.27%)
TSLA   1,645.61 (+5.84%)
GE   6.63 (-1.34%)
MU   46.79 (-3.49%)
AMD   82.89 (+0.34%)
T   29.87 (-1.03%)
F   7.07 (-0.56%)
ACB   10.04 (+2.45%)
GILD   68.02 (-1.19%)
NFLX   484.09 (+1.81%)
DIS   131.61 (-0.14%)
BAC   26.23 (-1.87%)
BA   175.75 (+0.18%)
S&P 500   3,385.39 (+0.15%)
DOW   27,942.37 (-0.12%)
QQQ   274.52 (+0.98%)
AAPL   461.35 (+2.06%)
MSFT   211.24 (+0.98%)
FB   263.09 (+1.23%)
GOOGL   1,527.18 (+1.32%)
AMZN   3,205.43 (+1.37%)
NVDA   464.00 (+1.40%)
CGC   17.36 (+0.64%)
BABA   254.51 (-0.27%)
TSLA   1,645.61 (+5.84%)
GE   6.63 (-1.34%)
MU   46.79 (-3.49%)
AMD   82.89 (+0.34%)
T   29.87 (-1.03%)
F   7.07 (-0.56%)
ACB   10.04 (+2.45%)
GILD   68.02 (-1.19%)
NFLX   484.09 (+1.81%)
DIS   131.61 (-0.14%)
BAC   26.23 (-1.87%)
BA   175.75 (+0.18%)
S&P 500   3,385.39 (+0.15%)
DOW   27,942.37 (-0.12%)
QQQ   274.52 (+0.98%)
AAPL   461.35 (+2.06%)
MSFT   211.24 (+0.98%)
FB   263.09 (+1.23%)
GOOGL   1,527.18 (+1.32%)
AMZN   3,205.43 (+1.37%)
NVDA   464.00 (+1.40%)
CGC   17.36 (+0.64%)
BABA   254.51 (-0.27%)
TSLA   1,645.61 (+5.84%)
GE   6.63 (-1.34%)
MU   46.79 (-3.49%)
AMD   82.89 (+0.34%)
T   29.87 (-1.03%)
F   7.07 (-0.56%)
ACB   10.04 (+2.45%)
GILD   68.02 (-1.19%)
NFLX   484.09 (+1.81%)
DIS   131.61 (-0.14%)
BAC   26.23 (-1.87%)
BA   175.75 (+0.18%)
S&P 500   3,385.39 (+0.15%)
DOW   27,942.37 (-0.12%)
QQQ   274.52 (+0.98%)
AAPL   461.35 (+2.06%)
MSFT   211.24 (+0.98%)
FB   263.09 (+1.23%)
GOOGL   1,527.18 (+1.32%)
AMZN   3,205.43 (+1.37%)
NVDA   464.00 (+1.40%)
CGC   17.36 (+0.64%)
BABA   254.51 (-0.27%)
TSLA   1,645.61 (+5.84%)
GE   6.63 (-1.34%)
MU   46.79 (-3.49%)
AMD   82.89 (+0.34%)
T   29.87 (-1.03%)
F   7.07 (-0.56%)
ACB   10.04 (+2.45%)
GILD   68.02 (-1.19%)
NFLX   484.09 (+1.81%)
DIS   131.61 (-0.14%)
BAC   26.23 (-1.87%)
BA   175.75 (+0.18%)
Log in

NASDAQ:RAREUltragenyx Pharmaceutical Stock Price, Forecast & News

$86.52
+2.71 (+3.23 %)
(As of 08/13/2020 12:47 PM ET)
Add
Compare
Today's Range
$84.18
Now: $86.52
$86.77
50-Day Range
$73.52
MA: $82.16
$90.00
52-Week Range
$31.99
Now: $86.52
$91.77
Volume4,258 shs
Average Volume545,984 shs
Market Capitalization$5.24 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.22
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
Read More
Ultragenyx Pharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARE
CUSIPN/A
Phone415-483-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$103.71 million
Book Value$11.32 per share

Profitability

Net Income$-402,730,000.00
Net Margins-188.51%

Miscellaneous

EmployeesN/A
Market Cap$5.24 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$86.52
+2.71 (+3.23 %)
(As of 08/13/2020 12:47 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RARE News and Ratings via Email

Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

How has Ultragenyx Pharmaceutical's stock price been impacted by COVID-19?

Ultragenyx Pharmaceutical's stock was trading at $45.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RARE shares have increased by 90.7% and is now trading at $86.47.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Ultragenyx Pharmaceutical?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ultragenyx Pharmaceutical
.

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Ultragenyx Pharmaceutical
.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) announced its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported ($1.91) EPS for the quarter, missing the Zacks' consensus estimate of ($1.68) by $0.23. The biopharmaceutical company earned $36.31 million during the quarter, compared to the consensus estimate of $36.74 million. Ultragenyx Pharmaceutical had a negative net margin of 188.51% and a negative return on equity of 56.12%. The company's revenue was up 99.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.82) EPS.
View Ultragenyx Pharmaceutical's earnings history
.

What price target have analysts set for RARE?

16 analysts have issued 12-month target prices for Ultragenyx Pharmaceutical's shares. Their forecasts range from $64.00 to $99.00. On average, they expect Ultragenyx Pharmaceutical's share price to reach $82.50 in the next year. This suggests that the stock has a possible downside of 4.6%.
View analysts' price targets for Ultragenyx Pharmaceutical
.

What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock?

Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:
  • 1. According to Zacks Investment Research, "Ultragenyx witnessed growth in the demand for Crysvita for both children and adults with X-linked hypophosphatemia in the United States. The drug's performance has been impressive so far. The company is also expanding the label of the drug and filed an sBLA for the same for the treatment of tumor-induced osteomalacia. The company’s NDA for a potential approval of its third therapy, UX007, in fatty acid oxidation disorders is under review with the FDA. Ultragenyx continues to advance two gene-therapy clinical programs — DTX401 for glycogen storage disease type Ia and DTX301 for ornithine transcarbamylase deficiency. However, being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses and the need for additional capital." (4/16/2020)
  • 2. Cowen Inc analysts commented, "Matinas reported 2Q19 with net loss of ($3.6M) and ended the period with $36.8M in cash on the balance sheet. The company should have runway through 2020 and through multiple catalysts; Omega-3 (OM3) asset MAT9001 and antifungal MAT2203 (amphotericin)." (8/15/2019)

Has Ultragenyx Pharmaceutical been receiving favorable news coverage?

Media coverage about RARE stock has trended extremely negative this week, InfoTrie reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ultragenyx Pharmaceutical earned a news sentiment score of -4.1 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days.
View the latest news about Ultragenyx Pharmaceutical
.

Who are some of Ultragenyx Pharmaceutical's key competitors?

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Exelixis (EXEL), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Crispr Therapeutics (CRSP), TG Therapeutics (TGTX), GW Pharmaceuticals PLC- (GWPH), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO) and GALAPAGOS NV/S (GLPG).

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the following people:
  • Emil D. Kakkis, President, Chief Executive Officer & Director
  • Wladimir Hogenhuis, Chief Operating Officer
  • Shalini Sharp, Chief Financial Officer & Executive Vice President
  • Dennis Karl Huang, Chief Technical Operations Officer & Senior VP
  • Eric Crombez, Chief Medical Officer

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional investors include Macquarie Group Ltd. (2.52%), First Trust Advisors LP (1.96%), Bank of New York Mellon Corp (1.25%), Hudson Bay Capital Management LP (0.22%), New York State Common Retirement Fund (0.21%) and Swiss National Bank (0.20%). Company insiders that own Ultragenyx Pharmaceutical stock include Clay B Siegall, Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski.
View institutional ownership trends for Ultragenyx Pharmaceutical
.

Which major investors are selling Ultragenyx Pharmaceutical stock?

RARE stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, UBS Group AG, Hudson Bay Capital Management LP, Macquarie Group Ltd., Prudential Financial Inc., CHI Advisors LLC, Russell Investments Group Ltd., and SG Americas Securities LLC. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Clay B Siegall, Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, and Theodore Alan Huizenga.
View insider buying and selling activity for Ultragenyx Pharmaceutical
.

Which major investors are buying Ultragenyx Pharmaceutical stock?

RARE stock was purchased by a variety of institutional investors in the last quarter, including First Trust Advisors LP, New York State Common Retirement Fund, Bank of New York Mellon Corp, Swiss National Bank, Motley Fool Asset Management LLC, Trexquant Investment LP, Rafferty Asset Management LLC, and State of Wisconsin Investment Board.
View insider buying and selling activity for Ultragenyx Pharmaceutical
.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $86.47.

How big of a company is Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical has a market capitalization of $5.24 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis.

What is Ultragenyx Pharmaceutical's official website?

The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.